CIDP Recovery: Milestones in Strength, Balance and Walking Over the First Months

Key Takeaways
- CIDP is defined by weakness and sensory loss progressing over at least eight weeks, and its slow onset is mirrored by a recovery measured in months.
- Myelin, the nerve insulation attacked in CIDP, can regrow over weeks to months, while damaged axons regrow far more slowly and sometimes incompletely, which explains why residual numbness or weakness is common.
- Strength usually returns before sensation, and hip and shoulder muscles usually recover before hands and ankles, so persistent foot drop does not mean treatment is failing.
- In the largest randomized immunoglobulin trial cited by the EAN/PNS guideline, roughly half of treated people improved on a disability scale versus about one in five on placebo, with most responders improving within the first several weeks.
- A true relapse is a sustained, progressive decline over days to weeks, not a rough couple of days after heat, infection or poor sleep, and prompt treatment shortens it.
- No diet or supplement has been shown to treat CIDP, and excess vitamin B6 can itself damage nerves, so nutrition advice should focus on correcting genuine deficiencies only.
Recovery from CIDP usually unfolds over months, not days. Many people notice the first gains in strength within a few weeks of starting immune treatment, while balance, sensation and confident walking often lag by several months. Progress is rarely a straight line; plateaus and small setbacks are common, and how far recovery goes depends largely on how much nerve fiber damage has occurred. Your neurology team tracks these milestones and adjusts the plan.
She had been a hiker. Then, over one long autumn, the stairs at work became a project, her toes stopped reporting where the floor was, and a coffee mug slipped from fingers that no longer felt like hers. By the time the diagnosis of CIDP arrived, what she wanted to know was not the Latin. It was: how long until I can trust my legs again?
That question sits at the heart of every conversation about the cidp recovery timeline, and it deserves an honest answer rather than a cheerful one. Chronic inflammatory demyelinating polyneuropathy is a slow-moving immune attack on the insulation of peripheral nerves. Slow to arrive, and slow to leave. But it is also one of the more treatable neuropathies, and the pattern of recovery, once treatment starts, follows a recognizable rhythm.
This explainer walks through that rhythm month by month: what tends to come back first, what lingers, what a flare looks like, and which changes should prompt a call to your care team rather than another week of waiting.
What CIDP actually does to a nerve, and why that shapes recovery
Picture an electrical cable. The copper wire in the middle is the axon, the long fiber that carries signals between your spinal cord and your muscles or skin. Wrapped around it is myelin, a fatty insulating layer that lets signals travel fast and cleanly. In CIDP, the immune system mistakenly strips away patches of that insulation. Signals slow down, scatter, or fail to arrive. The result is weakness, numbness, tingling and unsteadiness, typically in both arms and both legs, and typically worsening over at least eight weeks, which is the time cutoff that separates CIDP from its acute cousin, Guillain-Barré syndrome, according to the National Institute of Neurological Disorders and Stroke (NINDS).
This mechanism matters for the cidp recovery timeline in two ways. First, myelin can regrow. Once treatment quiets the immune attack, the specialized cells that make myelin can rebuild the insulation over weeks to months, which is why early improvement can be surprisingly brisk. Second, if the attack goes on long enough, the axon itself, the copper wire, begins to degenerate. Axons regrow far more slowly, roughly a millimeter a day at best, and some do not regrow at all. That is the biological reason neurologists talk about “residual” weakness or numbness and why the same diagnosis can produce very different recoveries.
So the honest framing is this: recovery in CIDP is mostly about how much of the problem is still insulation (fixable, relatively quickly) versus how much has become wire damage (slow, sometimes partial). Nerve conduction studies, the tests that measure signal speed along a nerve, help your team estimate that balance, and the estimate shapes what a realistic first year looks like for you.
Why the cidp recovery timeline is measured in months, not days
People coming out of a hospital stay for pneumonia or a knee replacement often carry a mental model of recovery as a steady daily climb. CIDP does not behave that way, and expecting it to is a reliable source of discouragement.

Three clocks run at once. The treatment clock is the fastest: immune therapies such as intravenous immunoglobulin (pooled antibodies from donated plasma), corticosteroids (anti-inflammatory hormones) and plasma exchange (a procedure that filters antibodies out of the blood) can begin to dampen the immune attack within days to a few weeks. The remyelination clock is slower, running over weeks to a few months as insulation is rebuilt. The axonal clock is slowest of all, stretching across many months and sometimes beyond a year, and it may never fully finish.
Because these clocks overlap, the visible curve of recovery tends to look like a staircase: a step up, a flat stretch, another step. The European Academy of Neurology and Peripheral Nerve Society (EAN/PNS) guideline advises clinicians to judge whether a first-line treatment is working over a period of roughly the first several months rather than after a single course, precisely because meaningful change can take that long to declare itself.
There is also a fourth clock that rarely gets named: deconditioning. Months of reduced activity before diagnosis shrink muscle, stiffen joints and dull the reflexes that keep you upright. Some of what feels like “CIDP not recovering” is actually ordinary fitness loss, and it responds to ordinary rehabilitation. Separating the two is one of the most useful things a physiotherapist does in the early months.
What the first few weeks after starting treatment usually look like
The first change many people describe is not strength at all. It is the sense that the decline has stopped. After weeks or months of each week being slightly worse than the last, a plateau can feel like a victory, and clinically it is one: stabilization is the first goal of treatment.
Within the first few weeks, some people notice early functional gains. A hand that could not manage buttons manages one. Getting up from a low chair takes one push instead of three. In the largest randomized trial of immunoglobulin for CIDP, cited in the EAN/PNS guideline, most of those who responded showed measurable improvement within the first several weeks of treatment, and about half of people receiving immunoglobulin improved on a standardized disability scale compared with roughly one in five receiving placebo. Those are trial figures, not a promise for any individual, but they do tell you that early response is common enough to watch for.
Corticosteroids often work more slowly. The guideline notes that a trial of steroids may need to run for a couple of months before a fair judgment can be made, so people on this route are sometimes asked to be patient longer before anyone changes course. That waiting is not neglect; it reflects how the medicine works.
Side effects also belong to this phase. Headache, fatigue or flu-like feelings in the days after an immunoglobulin course, mood changes or sleep disruption with steroids, and post-procedure tiredness after plasma exchange are all commonly reported. Report them; do not ration them silently. Your team weighs them against the benefit you are seeing and decides whether the plan needs adjusting. That decision always sits with the prescribing clinician.
Milestones in strength: what tends to come back first
Strength in CIDP usually returns in a recognizable order, and knowing it helps you read your own progress fairly. Large muscles close to the trunk, the hip flexors and shoulder muscles, are often the first to feel more dependable. That is partly because the nerve fibers supplying them are shorter, so remyelination has less distance to cover, and partly because these muscles were often affected later in the illness.

Hands and feet come next, and more slowly. Fine motor control, the coordination of small muscles that lets you thread a needle or pick a coin off a table, tends to lag behind raw grip. Many people can squeeze a hand firmly before they can write legibly. Ankle strength, which controls foot lift, is often the last of the leg muscles to recover, which is why foot drop (difficulty lifting the front of the foot when walking) can persist even when someone can climb stairs without a rail.
A practical way to track strength at home is with tasks rather than feelings:
- Rising from a standard dining chair without using your arms.
- Standing on tiptoe, then on heels, holding a counter for safety.
- Opening a new jar or a sealed water bottle.
- Carrying a bag of groceries from car to kitchen in one trip.
Clinicians often use formal versions of these ideas, including grip-strength meters and disability scales such as the INCAT score, a ten-point scale of arm and leg function used in CIDP trials. Whichever version you use, repeat the same task under the same conditions every couple of weeks. Day-to-day fluctuation is normal in CIDP; the trend over a month is what carries information.
Balance and sensation: the slower curve most people are not warned about
Ask someone six months into CIDP recovery what still bothers them and the answer is frequently not weakness. It is the feeling of walking on cotton wool, of not knowing exactly where the floor is in the dark, of reaching for a handrail on stairs they could climb without one in daylight. This is a sensory problem, and it recovers on its own timetable.
The culprit is impaired proprioception, the sense that tells your brain where your joints are without looking. Proprioceptive signals travel along some of the largest, most heavily insulated nerve fibers in the body, which makes them a prime target in a demyelinating illness. When they misfire, your brain compensates by leaning on vision. Turn off the lights or close your eyes in the shower and the compensation disappears, which is why so many falls in CIDP happen at night or in the bathroom.
Sensory recovery tends to trail motor recovery by weeks to months, and in some people a degree of numbness in the feet becomes permanent, as NINDS and MedlinePlus both note. That is not a failure of treatment; it usually reflects axonal loss that predates diagnosis.
The good news is that balance itself is trainable even when sensation is not fully back. Vestibular and balance rehabilitation teach the brain to weight its remaining inputs differently, and the effect on fall risk is real. A physiotherapist will typically progress from wide-base standing to narrow-base, from eyes open to eyes closed, from firm floor to foam. Do not skip this phase because you “just have numb feet.” Numb feet are precisely why it matters.
Walking milestones: a typical progression over the first months
Walking is the milestone people care about most, so it deserves a concrete map. The table below is a synthesis of how recovery commonly progresses in someone who responds to first-line treatment; it is not a schedule, and your own curve may be faster, slower or shaped differently. The timeframes reflect the general pattern described by NINDS and the EAN/PNS guideline of early motor response over weeks followed by slower sensory and functional gains over months.
| Typical window | Walking pattern often seen | What usually drives the change |
|---|---|---|
| Weeks 1–4 | Decline stops; short indoor walks feel less exhausting; may still need frame or two rails on stairs | Immune attack dampened; deconditioning begins to reverse |
| Weeks 4–12 | Longer indoor distances; one rail on stairs; outdoor walking on flat, familiar routes with a stick or cane | Proximal leg strength returns; early remyelination |
| Months 3–6 | Uneven ground manageable; steps without a rail in good light; foot drop may persist and an ankle brace may be fitted | Distal strength improving; balance retraining |
| Months 6–12+ | Community walking, shopping, gentle hiking for some; night-time and eyes-closed balance still the weak point | Slow sensory recovery; axonal regrowth where possible |
Two features of this map matter more than the dates. One is that aids change rather than vanish: a frame becomes a cane, a cane becomes an ankle-foot orthosis (a lightweight brace that holds the foot up), and the orthosis eventually stays in the closet on good days. Treating each aid as a tool rather than a defeat keeps people moving and lowers fall risk. The other is that plateaus of several weeks are normal at every stage and do not by themselves mean treatment has failed. A plateau that turns into decline, however, is different, and that distinction is covered in the sections on flares and red flags below.
Who usually recovers faster, and who is asked to wait
Neurologists cannot predict an individual’s course with precision, but a handful of features consistently shape expectations, and it is fair to ask where you sit.
Recovery tends to be quicker and fuller in people whose nerve studies show mostly demyelination with little axonal loss, whose symptoms are relatively recent, and whose CIDP fits the “typical” pattern of symmetric weakness in both arms and legs. The EAN/PNS guideline describes this typical form as the one with the most robust evidence for treatment response.
Recovery tends to be slower, or to plateau at a lower level, when there is substantial axonal damage on nerve studies, when symptoms have been present for years before diagnosis, when the pattern is purely sensory or confined to one limb, or when a person has other conditions that stress nerves, such as diabetes. In these situations the guideline notes that response to standard therapy can be less predictable.
Then there is the group asked to wait for a different reason: those whose diagnosis is still being confirmed. CIDP has several mimics, including hereditary neuropathies and neuropathies linked to abnormal blood proteins, and starting immune treatment before the picture is clear can muddy the diagnosis. If your team is running further blood tests, a lumbar puncture (sampling spinal fluid through a needle in the lower back) or a nerve biopsy before committing, that pause is diagnostic diligence, not delay.
People on corticosteroids may also be asked to wait longer before a verdict on effectiveness, because this class works more gradually than immunoglobulin or plasma exchange. Whichever group you are in, the question worth asking is not “why not faster” but “what would change the plan, and when will we know.”
How long do CIDP flare-ups last, and what is a relapse?
Not every bad day is a flare. Fatigue, heat, a poor night’s sleep or a viral illness can make existing CIDP symptoms feel louder for a day or two without any new nerve damage. A true relapse is different: it is new or worsening weakness, numbness or unsteadiness that persists and progresses over days to weeks, reflecting renewed immune activity on the nerves.
How long a flare lasts depends mostly on how quickly it is recognized and treated. Because immune therapies wear off, many people on maintenance treatment notice a predictable dip in the days before their next course is due, a pattern sometimes called “wearing off.” When that dip becomes a sustained slide, neurologists often shorten the interval between courses or adjust the approach, and improvement typically follows within weeks of the adjustment, mirroring the initial response.
NINDS describes CIDP as following one of three broad courses: relapsing-remitting, where flares are separated by periods of recovery; progressive, where decline is steady; or monophasic, where a single episode is followed by lasting improvement. Which course you follow influences how flares feel and how treatment is spaced.
Untreated, a flare can continue for weeks or months, which is why the practical advice is simple: do not wait it out. Keep a brief symptom log so you can tell your team when the change began and how it has progressed. A phrase like “I could manage the stairs without a rail two weeks ago and now I need both hands” is far more useful to a neurologist than “I feel worse.” Recovery from a promptly treated flare often, though not always, returns you to your previous baseline; recovery from a prolonged one may not, because axons pay the price of delay.
Is exercise good for CIDP? What the evidence and clinicians say
Yes, with a qualifier that matters. Exercise does not treat the immune attack; that is the medicine’s job. What exercise does is reverse the deconditioning that piles on top of nerve damage, protect joints that weak muscles no longer stabilize, and retrain balance. Rehabilitation guidance from the NHS for peripheral neuropathy and from NINDS for CIDP both place physiotherapy alongside immune treatment rather than after it.
The qualifier is intensity. Damaged nerves cannot recruit muscle efficiently, so a workout that would be moderate for a healthy person can leave someone with CIDP profoundly fatigued for a day or more. This post-exertional fatigue is not a sign that exercise is harming the nerves, but it is a sign the dose was too high. The working principle most neuro-physiotherapists use is “work to comfortable effort, never to exhaustion, and judge by how you feel the next morning.”
A sensible early program usually includes:
- Low-impact aerobic activity such as stationary cycling, pool walking or short flat walks, building duration before speed.
- Strength work using body weight or light resistance bands, focusing on hips, thighs and shoulders first.
- Balance drills progressed as described earlier, always with something to hold.
- Gentle stretching of calves and hamstrings, since tight calves worsen foot drop.
Avoid heavy lifting with a numb grip and avoid exercising barefoot when foot sensation is poor; you may not feel a blister or a cut. If a session leaves you weaker for more than a day, scale back and mention it at your next appointment. A supervised program with a physiotherapist experienced in neurological conditions is worth requesting early, because the right starting point is hard to judge from the inside.
How many people with CIDP end up in a wheelchair? An honest answer
This is one of the most-searched questions about CIDP, and the most truthful response is that no reliable single figure exists, so be wary of any source that offers one with confidence.
What the evidence does show is this. CIDP is classed as a treatable neuropathy, and the majority of people who receive standard immune therapy improve or stabilize, according to NINDS and the EAN/PNS guideline. MedlinePlus notes that outcomes range from full recovery to permanent loss of some nerve function, with many people falling between. A minority live with significant lasting disability, and within that minority some use a wheelchair for longer distances or during flares while walking indoors.
Several factors push the odds one way or the other. Delay to diagnosis and treatment is the biggest modifiable one, because axonal loss accumulates while the disease is untreated. Response to first-line therapy is the second: people who improve on their initial treatment tend to keep that ground with maintenance. Age, other medical conditions and the specific subtype of CIDP also play a role.
Two points are worth holding onto. A wheelchair is a mobility tool, not an end point; plenty of people use one for a period during a flare and then walk out of the clinic months later. And using one during a bad stretch is a safer choice than falling. If fear of a wheelchair is driving you to push through unsafe walking, tell your therapist. The goal in CIDP rehabilitation is mobility with the least risk, not walking at any cost.
Fatigue, pain and the invisible part of recovery
Strength and walking are what other people can see. Fatigue and pain are what people with CIDP most often say others do not understand, and both can outlast the visible deficits.
Fatigue in CIDP is physiological, not motivational. Demyelinated nerves conduct inefficiently, so every movement costs more signal for less result. Muscles weakened by months of disuse tire faster. Treatment itself can add a layer: immunoglobulin courses commonly leave people washed out for a day or two, and corticosteroids can disturb sleep. The fatigue tends to improve as strength returns, but it often trails behind by months, and some people describe a persistent lower ceiling on stamina even after their examination looks normal.
Pain follows a similar pattern. Some people have little; others have burning, electric or deep aching pain in the feet and hands that reflects irritable, partially repaired sensory nerves. Neuropathic pain, pain generated by damaged nerves rather than by injury to tissue, does not respond to ordinary pain relievers in the way a sprain would, and it is treated with different classes of medicine. Which class, whether any, and for how long is a decision for your neurologist or pain specialist; the mechanism matters more here than the name.
Practical management overlaps a great deal with good general care: protect sleep, pace activity across the week rather than clustering it, keep feet warm and inspect them regularly if they are numb, and ask about referral to a pain service if pain is limiting rehabilitation. Mood also belongs in this conversation. A slow, non-linear recovery from a rare illness is a recognized strain, and asking for psychological support is part of treatment, not a detour from it.
What people often get wrong about CIDP recovery
Recovery from a rare disease breeds myths, partly because people compare notes online with others whose disease is not the same. These are the misconceptions clinicians hear most.
“If treatment worked, I would be back to normal by now.” Treatment stops the attack; it does not instantly rebuild what was damaged. The EAN/PNS guideline frames response over months, and residual deficits from axonal loss are common even in people whose treatment is working well.
“My recovery should look like the recovery stories I read about Guillain-Barré.” GBS is a single acute episode that typically improves steadily over months; the NHS describes most people recovering substantially within a year. CIDP is chronic and often relapsing, so its curve is a staircase rather than a ramp, and comparing the two is a recipe for false alarm.
“A bad week means the medicine has stopped working.” Fluctuation is built into CIDP. Heat, infection, poor sleep and the tail end of a treatment cycle all cause temporary dips. A sustained, progressive decline over weeks is the signal; a rough few days is noise.
“Feeling stronger means I can stop treatment.” In relapsing CIDP, symptoms frequently return when maintenance therapy is withdrawn. Whether and when to trial a reduction is a structured decision made with your neurologist, never a solo one.
“A special diet or supplement can fix the nerves.” No diet has been shown to treat CIDP. Correcting a genuine vitamin deficiency helps nerves generally, but megadoses of vitamins, particularly B6, can themselves cause neuropathy, as NINDS notes in its guidance on peripheral neuropathy causes.
“Needing a brace or cane means I am going backwards.” Aids reduce falls and let you walk further, which is exactly what rehabilitation needs. Using one is a strategy, not a verdict.
Tracking your own progress: why a diary beats memory
Human memory is a poor instrument for slow change. Ask most people how they compare with two months ago and they will anchor on how they feel today. A simple written record fixes this, and it changes the quality of every appointment.
Keep the record short and repeatable. Once a week, on the same day and roughly the same time, note four things: how long you can walk before you need to rest, whether you used a rail or aid on stairs, a task from the strength list earlier in this article (chair rise, jar, tiptoe) and a fatigue score from zero to ten. Add a line for any new symptom and any treatment given that week, including side effects. That is the whole diary. Five minutes.
Over three months this produces something no clinician can get from a fifteen-minute visit: a trend line. It shows whether a plateau is truly flat or gently rising. It reveals a wearing-off pattern before each treatment course that might justify a change in spacing. It distinguishes a two-day dip after a viral cold from a three-week decline that needs attention. The EAN/PNS guideline emphasizes objective measures of response, and your diary is the patient-side version of that principle.
Some people add a timed walk over a fixed indoor distance or a phone video of themselves walking a hallway once a month. Both are legitimate, and the video in particular can be striking: foot clearance and arm swing change in ways you cannot feel. Bring the diary to every appointment and offer it before you are asked. Neurologists make better decisions with better data, and in CIDP, where the decisions are about spacing and continuing treatment over years, that data is yours to provide.
Questions to ask your care team about your cidp recovery timeline
Appointments are short and the diagnosis is complicated, so it helps to arrive with questions written down. These are the ones that tend to produce the most useful answers.
- On my nerve studies, how much of the problem looks like demyelination and how much like axonal loss? What does that mean for how far I might recover?
- Which course does my CIDP seem to be following: relapsing, progressive or a single episode?
- How will we know whether this treatment is working, and by roughly when? What would make you change the plan?
- What does a relapse look like for me specifically, and how quickly should I contact you if I think one is starting?
- Am I likely to need maintenance treatment long term, and how will we decide whether to try spacing it out?
- Can I be referred to a physiotherapist and occupational therapist with neurological experience? What should I avoid in exercise right now?
- Should I be assessed for an ankle brace or other aids to lower my fall risk?
- Which of my symptoms are likely to improve, and which might be permanent?
- Are there vaccinations, infections or medicines I should be careful about while on immune treatment?
- Who do I call between appointments, and what counts as urgent?
Two further habits pay off. Ask your team to write down the plan and the decision points, because the details of a months-long strategy are hard to hold in your head on the day. And bring someone with you when you can; a second listener catches what the first misses, and recovery from CIDP is easier when the people around you understand the timeline too. Every one of these questions has an answer that depends on your individual picture, which is exactly why they belong in the consulting room rather than in a search engine.
When to call your doctor: red flags during CIDP recovery
Most of the ups and downs of CIDP can wait for a scheduled appointment. A few cannot. Contact your neurology team promptly, or seek urgent care if you cannot reach them, when you notice any of the following.
- Weakness that is clearly worsening over days rather than fluctuating, especially if it is spreading upward from the legs to the arms or trunk.
- Any difficulty breathing, shortness of breath when lying flat, or a weak cough. Breathing muscle involvement is uncommon in CIDP but is an emergency when it occurs.
- Trouble swallowing, slurred speech or new facial weakness.
- New problems controlling your bladder or bowels.
- A fall with head injury, or repeated falls in a short period.
- Signs of a blood clot after immunoglobulin or plasma exchange: a swollen, painful calf, or sudden chest pain and breathlessness.
- Fever or signs of infection while on corticosteroids or other immunosuppressants, which can blunt your body’s usual warning signs.
- Severe headache, stiff neck or confusion in the days after an immunoglobulin course.
- A wound or ulcer on a numb foot, even a small one, since impaired sensation delays healing and hides infection.
Less urgent but still worth a call within a few days: a wearing-off pattern that is arriving earlier before each treatment, new pain that is disrupting sleep, or a plateau that has quietly turned into a slow decline over two to three weeks. NINDS and MedlinePlus both emphasize that untreated relapses risk permanent nerve damage, so the general rule is to err toward calling. Your team would rather hear about a false alarm than about a flare that ran for a month unreported. Whatever you observe, the decision about what to do next belongs with the clinicians who know your history and your test results.
Frequently asked questions
How long does it take to recover from CIDP after starting treatment?
Early gains in strength often appear within a few weeks of starting immune treatment, while balance, sensation and confident walking typically improve over several months. The EAN/PNS guideline frames treatment response over the first few months rather than weeks, and some deficits from axonal damage may be permanent. Your neurologist judges your individual timeline using nerve studies and repeated functional assessments.
How long do CIDP flare-ups last?
A CIDP flare lasts as long as the renewed immune attack goes untreated, which can be weeks to months. Once recognized and treated, or once maintenance treatment is re-timed, improvement commonly follows within weeks. Brief dips of a day or two caused by heat, infection or fatigue are not true flares. Persistent, progressive worsening over days should be reported to your neurology team without waiting.
Is exercise good for CIDP?
Yes, when paced carefully. Exercise reverses the deconditioning that adds to nerve-related weakness, protects joints and retrains balance, and physiotherapy is a standard part of CIDP care according to NINDS. The key is moderate effort that does not leave you significantly weaker the next day. Low-impact aerobic work, light resistance training and supervised balance drills are typical starting points; a neurological physiotherapist can tailor the program.
How many people with CIDP end up in a wheelchair?
There is no reliable single percentage, and sources that claim one should be read cautiously. The majority of people treated for CIDP improve or stabilize, according to NINDS and the EAN/PNS guideline, while a minority live with significant lasting disability, some of whom use a wheelchair for distance or during flares. Delay to diagnosis and the extent of axonal loss are the strongest influences on this outcome.
What foods should I avoid if I have CIDP?
No specific food has been shown to worsen or improve CIDP, so there is no evidence-based avoidance list. General nerve health advice applies: limit alcohol, which damages peripheral nerves, avoid high-dose vitamin B6 supplements, which can cause neuropathy, and correct any genuine deficiency such as low vitamin B12 if your doctor identifies one. People on corticosteroids may receive separate advice about salt, sugar and bone health.
What is the typical cidp treatment response time for different therapies?
Immunoglobulin and plasma exchange often produce noticeable change within a few weeks in people who respond, while corticosteroids usually work more gradually and may need a couple of months before their effect can be judged, according to the EAN/PNS guideline. These are typical ranges, not promises. Your neurologist sets a review point in advance and decides whether to continue, adjust or switch based on measured change.
Why is my balance still poor when my strength has come back?
Balance depends on proprioception, the joint-position sense carried by large sensory nerve fibers that are heavily affected in CIDP, and sensory recovery usually lags weeks to months behind motor recovery. Some numbness may persist permanently if axons were damaged. Balance can still improve through targeted rehabilitation that trains the brain to rely more on vision and inner-ear input, and an ankle brace may reduce fall risk.
Is CIDP recovery different from Guillain-Barré recovery?
Yes. Guillain-Barré syndrome is a single acute episode that typically improves steadily, with the NHS noting most people recover substantially within a year. CIDP is chronic, progresses over at least eight weeks, and often relapses, so its recovery follows a staircase pattern with plateaus and dips, and many people need ongoing maintenance treatment. Comparing the two timelines directly tends to cause unnecessary alarm.
Can CIDP symptoms return after recovery?
They can, particularly in the relapsing form of the disease. NINDS describes relapsing-remitting, progressive and single-episode courses, and in relapsing CIDP symptoms frequently return when maintenance treatment is spaced too widely or withdrawn. Any decision to reduce or stop treatment is made gradually with your neurologist, with a plan for what to do if symptoms recur. Keeping a symptom diary helps catch early signs.
What signs during CIDP recovery mean I should call my doctor urgently?
Call urgently for weakness that is clearly worsening over days, any breathing or swallowing difficulty, slurred speech, new bladder or bowel problems, a swollen painful calf or sudden chest pain after treatment, fever while on immunosuppressive medicine, or a fall with head injury. A slow decline over two to three weeks or an earlier wearing-off pattern before each treatment also warrants a prompt, if less urgent, call.
References
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), National Institute of Neurological Disorders and Stroke (NIH)
- Chronic inflammatory polyneuropathy, MedlinePlus Medical Encyclopedia
- Peripheral neuropathy, NHS
- Guillain-Barré syndrome, NHS
This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.
More from the Blog
Movement Disorders Treatment: How Tremor, Dystonia and Parkinsonism Are Managed Differently
Movement disorders are treated according to the circuit that is misfiring, not the symptom alone. Essential tremor is usually managed with beta blockers or…
Headache with Neck Pain or Stiffness: Common Causes, Meningitis Warning Signs and When It Is Urgent
Headache with neck stiffness is most often caused by tense neck muscles, prolonged poor posture, a tension-type headache or a headache that starts in…
Caregiver Guidance in Alzheimer’s Disease: Sleep, Fall Prevention and Daily Structure
Alzheimer's caregiver guidance centers on three practical levers: protect sleep with daylight, movement and a calm evening routine; prevent falls by simplifying the home…
How Are Sleep and Mood Changes Managed in Dementia Care Without Losing Daily Routine?
Sleep and mood changes in dementia are usually managed by keeping the day predictable first: consistent wake and bed times, morning daylight, regular meals,…
How Physical, Speech and Occupational Therapy Support Daily Life in Parkinson’s Disease
Physical, occupational and speech therapy support daily life with Parkinson's disease by retraining movements the brain no longer runs automatically. Physical therapists work on…
Neurosarcoidosis Treatment: How Specialists Control Inflammation and Prevent Relapses
Neurosarcoidosis is usually treated in stages: corticosteroids to dampen inflammation quickly, then steroid-sparing immune medicines such as antimetabolites to hold that control while steroid…






